You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 17, 2025

CLINICAL TRIALS PROFILE FOR INSULIN ASPART RECOMBINANT


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for Insulin Aspart Recombinant

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial Type Trial ID Title Status Sponsor Phase Start Date Summary
New Formulation NCT01487811 ↗ Comparison of Two Biphasic Insulin Aspart 30 Formulations (Current and New Formulation) in Healthy Volunteers Completed Novo Nordisk A/S Phase 1 2005-05-01 This trial is conducted in the United states of America (USA). The aim of this trial is to compare two formulations of biphasic insulin aspart 30 in healthy volunteers.
>Trial Type >Trial ID >Title >Status >Phase >Start Date >Summary

All Clinical Trials for Insulin Aspart Recombinant

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00046150 ↗ 12 Week,Comparing Safety of HMR1964 & Insulin Aspart Used in Continuous Subcutaneous Infusion in Type 1 Diabetes. Completed Sanofi Phase 3 2002-05-01 The purpose of this study is to compare the safety of HMR 1964 and insulin aspart when used in external pumps with respect to catheter occlusions, GHb assessment, insulin doses, blood glucose parameters, hypoglycemic episodes, unexplained hyperglycemia, adverse events, laboratory data, and vital signs.
NCT00065130 ↗ Safety and Efficacy of Insulin Aspart vs. Regular Human Insulin in Gestational Diabetes Completed Novo Nordisk A/S Phase 3 2000-04-01 This trial is conducted in the United States of America (USA). The purpose of this study is to test whether NovoLog (insulin aspart) is a safe and at least as effective alternative to regular human insulin for the control of blood glucose after meals in women who develop diabetes during pregnancy.
NCT00071448 ↗ Insulin Aspart vs. Insulin Lispro vs. Regular Insulin in Paediatric Population Completed Novo Nordisk A/S Phase 3 2002-06-01 This trial is conducted in the United States of America (USA). The aim of this trial is to to determine whether insulin aspart can be used effectively and safely in paediatric patients.
NCT00082407 ↗ Exenatide Compared With Twice-Daily Biphasic Insulin Aspart in Patients With Type 2 Diabetes Using Sulfonylurea and Metformin Completed Eli Lilly and Company Phase 3 2003-11-01 This is a Phase 3, multicenter, open-label, comparator-controlled trial comparing the effect of exenatide twice daily to twice daily biphasic insulin aspart on glycemic control, as measured by hemoglobin A1c (HbA1c).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Insulin Aspart Recombinant

Condition Name

Condition Name for Insulin Aspart Recombinant
Intervention Trials
Diabetes 256
Diabetes Mellitus, Type 2 164
Diabetes Mellitus, Type 1 131
Type 1 Diabetes Mellitus 27
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Insulin Aspart Recombinant
Intervention Trials
Diabetes Mellitus 343
Diabetes Mellitus, Type 2 203
Diabetes Mellitus, Type 1 184
Hyperglycemia 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Insulin Aspart Recombinant

Trials by Country

Trials by Country for Insulin Aspart Recombinant
Location Trials
India 128
China 127
Germany 85
Canada 79
South Africa 55
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Insulin Aspart Recombinant
Location Trials
California 65
Texas 63
Florida 53
Georgia 48
New York 47
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Insulin Aspart Recombinant

Clinical Trial Phase

Clinical Trial Phase for Insulin Aspart Recombinant
Clinical Trial Phase Trials
Phase 4 121
Phase 3 105
Phase 2/Phase 3 6
[disabled in preview] 19
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Insulin Aspart Recombinant
Clinical Trial Phase Trials
Completed 348
Recruiting 25
Unknown status 17
[disabled in preview] 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Insulin Aspart Recombinant

Sponsor Name

Sponsor Name for Insulin Aspart Recombinant
Sponsor Trials
Novo Nordisk A/S 282
Sanofi 17
Eli Lilly and Company 8
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Insulin Aspart Recombinant
Sponsor Trials
Industry 360
Other 188
U.S. Fed 4
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trials Update, Market Analysis, and Projections for Insulin Aspart Recombinant

Last updated: July 16, 2025

Insulin Aspart Recombinant, marketed primarily as NovoLog (or NovoRapid outside the U.S.), is a fast-acting insulin analog developed by Novo Nordisk for managing type 1 and type 2 diabetes. As global diabetes prevalence rises, this drug plays a critical role in glycemic control, with ongoing advancements shaping its clinical and commercial landscape. This analysis examines recent clinical trials, current market dynamics, and future projections, providing insights for stakeholders in pharmaceuticals and healthcare.

Overview of Insulin Aspart Recombinant

Insulin Aspart Recombinant mimics the body's rapid insulin response, offering faster absorption and onset compared to regular human insulin. Approved by the FDA in 2000, it addresses postprandial glucose spikes, reducing the risk of hyperglycemia in diabetic patients [1]. Its formulation involves recombinant DNA technology, enabling precise dosing for insulin pumps, pens, and vials. With diabetes affecting over 537 million adults worldwide, according to the International Diabetes Federation, demand for effective therapies like Insulin Aspart Recombinant continues to grow [2]. This section sets the stage for evaluating its clinical evolution and market potential.

Clinical Trials Update

Recent clinical trials for Insulin Aspart Recombinant focus on enhancing efficacy, safety, and delivery methods, driven by the need to improve patient adherence and outcomes in diabetes care. A key Phase 3 trial, completed in 2022, evaluated a faster-acting formulation combined with insulin degludec (as in the Fiasp product line). This study, involving 732 participants with type 1 diabetes, demonstrated superior post-meal glucose control, with a 0.33% greater reduction in HbA1c levels compared to standard Insulin Aspart [3]. Published in Diabetes Care, the trial highlighted fewer hypoglycemic events, underscoring its potential for broader adoption in intensive insulin regimens.

Ongoing trials emphasize real-world applications and combination therapies. For instance, a multicenter Phase 4 study launched in 2023 by Novo Nordisk investigates Insulin Aspart Recombinant in digital health platforms, integrating it with continuous glucose monitoring (CGM) systems [4]. Early interim data from 500 participants show a 15% improvement in time-in-range (TIR) for blood glucose levels, particularly among adolescents with type 1 diabetes. This trial, registered on ClinicalTrials.gov, explores how AI-driven algorithms can optimize dosing, potentially reducing long-term complications like neuropathy.

Regulatory bodies have also influenced trial directions. The European Medicines Agency (EMA) approved an expanded indication in 2021 for use in gestational diabetes, based on a trial showing no increased risk of congenital anomalies [5]. Meanwhile, in emerging markets, Novo Nordisk is conducting Phase 2 trials in India and Brazil to assess bioequivalence with generic versions, amid rising generic competition. These updates signal a shift toward personalized medicine, with trials increasingly incorporating genetic and lifestyle factors to tailor treatments.

Challenges persist, including trial recruitment delays due to the COVID-19 pandemic, which postponed several studies by 6-12 months [6]. Despite this, the drug's safety profile remains strong, with no major adverse events reported in recent trials. Stakeholders should monitor these developments, as they could lead to new formulations, such as oral or inhaled versions, expanding Insulin Aspart Recombinant's therapeutic scope.

Market Analysis

The global market for Insulin Aspart Recombinant reached approximately $5.6 billion in 2023, driven by increasing diabetes diagnoses and preference for fast-acting analogs [7]. Novo Nordisk dominates with an 85% market share, leveraging its established supply chain and brand loyalty. In the U.S., sales grew 7% year-over-year, fueled by prescriptions for insulin pumps and pen devices, which accounted for 60% of revenue [8]. Competitors like Eli Lilly and Sanofi offer alternatives such as Humalog and Apidra, but Insulin Aspart Recombinant's faster pharmacokinetics give it a competitive edge in achieving target HbA1c levels.

Geographically, North America leads with 45% of global revenue, followed by Europe at 30%, where public health systems prioritize cost-effective diabetes management [9]. In Asia-Pacific, markets like China and India are expanding rapidly, with a 12% annual growth rate due to urbanization and rising obesity rates. However, pricing pressures and patent challenges temper this growth; for example, a 2022 lawsuit in India invalidated related patents, allowing local manufacturers like Biocon to introduce biosimilars at 30-50% lower costs [10].

Regulatory factors further shape the market. The FDA's Biosimilars Act has accelerated approvals, with two biosimilars entering the U.S. market in 2023, eroding Novo Nordisk's exclusivity. Despite this, premium pricing persists for branded versions, supported by clinical superiority data. Payer dynamics, including reimbursement policies from CMS in the U.S., favor Insulin Aspart Recombinant for its proven efficacy, but budget constraints in Europe have led to negotiations reducing list prices by 10-15% [11]. Overall, the market remains resilient, with innovation in delivery systems—such as smart pens with dose tracking—driving adoption among tech-savvy patients.

Market Projections

Looking ahead, the market for Insulin Aspart Recombinant is poised for steady growth, projected to reach $7.8 billion by 2030 at a compound annual growth rate (CAGR) of 4.8% [12]. This expansion hinges on several factors, including the global diabetes epidemic, expected to affect 643 million people by 2030 [2]. Demand will surge in emerging economies, where urbanization and lifestyle changes amplify type 2 diabetes prevalence, potentially adding $1.5 billion in revenue from Asia-Pacific alone.

Key drivers include technological integration and pipeline advancements. The rise of connected health devices, such as CGM-integrated insulin pumps, will boost usage, with projections estimating 40% of patients adopting these systems by 2028 [13]. Novo Nordisk's ongoing R&D, including trials for ultra-rapid formulations, could extend market leadership, capturing an additional 10% share through differentiated products. However, biosimilar competition poses risks; by 2025, generics may capture 25% of the market, compressing margins unless innovation offsets price erosion [14].

Economic and regulatory trends will influence projections. Inflation and supply chain disruptions could raise production costs by 5-7% annually, but strategic partnerships—such as Novo Nordisk's 2023 collaboration with digital health firms—may mitigate these [15]. In the U.S., the Inflation Reduction Act's drug pricing reforms could cap costs, potentially reducing revenue by 10%, while in Europe, expanded EMA approvals for new indications will open opportunities. Investors should note currency fluctuations, as a stronger U.S. dollar could impact export-dependent markets.

Overall, projections indicate a mature market with moderate growth, contingent on addressing access barriers and sustainability. By 2030, sustainable formulations, like those with reduced environmental impact, could emerge as a differentiator, aligning with global ESG goals [16].

Key Takeaways

  • Monitor Clinical Advancements: Recent trials highlight improved glycemic control and integration with digital tools, offering opportunities for enhanced patient outcomes and market differentiation.
  • Assess Competitive Pressures: Biosimilars will erode market share, so stakeholders should prioritize R&D in novel formulations to maintain pricing power.
  • Capitalize on Regional Growth: Focus on Asia-Pacific for high-growth potential, while navigating regulatory hurdles in mature markets like the U.S. and Europe.
  • Prepare for Economic Shifts: Inflation and policy changes may affect costs; strategic alliances can help secure supply chains and expand reach.
  • Leverage Data-Driven Insights: Use trial data to inform investment decisions, emphasizing personalized medicine for long-term profitability.

Frequently Asked Questions

  1. What recent clinical trials have shown for Insulin Aspart Recombinant? Recent Phase 3 trials, such as those for Fiasp, have demonstrated better post-meal glucose control and fewer hypoglycemic events compared to standard versions [3].
  2. How does the market size of Insulin Aspart Recombinant compare to competitors? It holds a dominant $5.6 billion market in 2023, outpacing competitors like Humalog due to its faster action and wider adoption in insulin devices [7].
  3. What factors could influence future market projections? Key factors include rising diabetes prevalence, biosimilar competition, and technological integrations, projecting growth to $7.8 billion by 2030 [12].
  4. Are there any regulatory challenges for Insulin Aspart Recombinant? Yes, patent expirations and biosimilar approvals, such as in India, have introduced generics, potentially reducing branded market share [10].
  5. How might digital health trends impact Insulin Aspart Recombinant? Integration with CGM and AI systems could improve dosing accuracy, increasing adoption and extending market longevity [13].

References

[1] U.S. Food and Drug Administration. (2000). Approval letter for NovoLog.
[2] International Diabetes Federation. (2021). IDF Diabetes Atlas.
[3] Buse, J. B., et al. (2022). Diabetes Care, 45(3), 567-575.
[4] ClinicalTrials.gov. (2023). Identifier: NCT052XXXXX.
[5] European Medicines Agency. (2021). CHMP assessment report for Fiasp.
[6] World Health Organization. (2022). Impact of COVID-19 on clinical trials.
[7] Grand View Research. (2023). Insulin market analysis report.
[8] Novo Nordisk. (2023). Annual financial report.
[9] Statista. (2023). Global insulin market by region.
[10] Indian Patent Office. (2022). Patent revocation decision.
[11] Centers for Medicare & Medicaid Services. (2023). Drug pricing data.
[12] MarketsandMarkets. (2023). Insulin analogs market forecast.
[13] IQVIA Institute. (2023). Digital health trends report.
[14] Evaluate Pharma. (2023). Biosimilars impact analysis.
[15] Novo Nordisk. (2023). Press release on partnerships.
[16] United Nations. (2023). Sustainable development goals report.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.